Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

23.53
-1.1700-4.74%
Post-market: 23.530.00000.00%18:46 EDT
Volume:294.10K
Turnover:7.01M
Market Cap:699.58M
PE:-28.23
High:24.65
Open:24.60
Low:23.44
Close:24.70
52wk High:44.28
52wk Low:14.59
Shares:29.73M
Float Shares:25.11M
Volume Ratio:0.97
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8334
EPS(LYR):-0.8334
ROE:-5.21%
ROA:-2.56%
PB:1.49
PE(LYR):-28.23

Loading ...

Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis

Reuters
·
Dec 17, 2025

Should Expert Endorsement of DecisionDx-Melanoma’s Prognostic Value Require Action From Castle Biosciences (CSTL) Investors?

Simply Wall St.
·
Dec 16, 2025

Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares

Reuters
·
Dec 16, 2025

Castle Biosciences Inc : Btig Raises Target Price to $50 From $38

THOMSON REUTERS
·
Dec 12, 2025

Castle Biosciences Study Confirms TissueCypher Outperforms Traditional Methods in Predicting Esophageal Cancer Risk

Reuters
·
Dec 12, 2025

Systematic Review and Meta-Analysis Confirms Tissuecypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

THOMSON REUTERS
·
Dec 12, 2025

Castle Biosciences Is Maintained at Buy by BTIG

Dow Jones
·
Dec 12, 2025

Castle Biosciences’ DecisionDx-Melanoma Endorsed as Best-Practice Tool by Expert Panel

Reuters
·
Dec 09, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 09, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 02, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Disposal of Common Shares

Reuters
·
Nov 27, 2025

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Reports Disposal of Common Shares

Reuters
·
Nov 25, 2025

Castle Biosciences (CSTL): Evaluating Valuation After New Data on DecisionDx-Melanoma Diagnostic Advances

Simply Wall St.
·
Nov 22, 2025

Scibase And Castle Biosciences Expand Collaboration

Reuters
·
Nov 20, 2025

Castle Biosciences Unveils New Data Showing DecisionDx-Melanoma Improves Sentinel Lymph Node Biopsy Decision Making

Reuters
·
Nov 14, 2025

New Data Confirms Performance of Decisiondx®-Melanoma to Identify Patients With Less Than Five Percent Risk of Sentinel Lymph Node Positivity

THOMSON REUTERS
·
Nov 14, 2025

Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Kristen M. Oelschlager, Chief Operating Officer, Reports Disposal of Castle Biosciences Inc. Common Shares

Reuters
·
Nov 14, 2025

Castle Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference

Reuters
·
Nov 11, 2025

SciBase Holding AB reports Q3 net sales of SEK 10.3 million and loss after tax of SEK 18.8 million

Reuters
·
Nov 07, 2025